TAIPEI and SAN DIEGO, Dec. 23, 2025 — Senhwa Biosciences outlined progress across its AI-enabled drug development platform at its 2025 annual investor conference, positioning the company amid a generational transition in immuno-oncology as major products approach patent expirations before 2030.
Pharmaceutical companies are seeking next-generation assets that can be combined across multiple tumor types and potentially become new standards of care. Senhwa said it is addressing this demand through a strategy that integrates artificial intelligence validation, precision clinical development and global pharmaceutical partnerships.
An independent analysis by Google DeepMind applied the C2S-Scale biological AI model to more than 4,000 drug candidates and identified Senhwa’s Silmitasertib (CX-4945) as a top candidate for reinvigorating the immune response to cancer. The study, supported by Google’s computing infrastructure and DeepMind models and accompanied by preclinical validation at Yale University, found that CX-4945 enhances tumor antigen presentation, a mechanism important for improving immune recognition of cancer cells.
Senhwa said the finding supports CX-4945’s potential as an immune-sensitizing agent and highlights its relevance for converting immunologically “cold” tumors, which often respond poorly to immunotherapy, into more immune-active states.
The company also announced a clinical collaboration with BeOne Medicines to evaluate Senhwa’s Pidnarulex (CX-5461) in combination with BeOne’s commercially approved PD-1 inhibitor tislelizumab. The initial trials will focus on pancreatic cancer and advanced solid tumors, including immunotherapy-resistant melanoma.
Senhwa describes CX-5461 as a first-in-class small molecule with a dual mechanism: stabilizing DNA G-quadruplex structures and inhibiting RNA polymerase I. According to the company, this dual activity induces replication stress in tumor cells and activates the innate cGAS–STING pathway, promoting immune activation in previously cold tumor environments. Senhwa said robust preclinical data support the use of CX-5461 to enhance the efficacy of existing immunotherapies and as a candidate for combination regimens.
The company said its pathway-level, multi-target approach aims to position CX-5461 as a potential next-generation backbone for cancer treatments that incorporate immunotherapy, rather than as an asset limited to a single indication. That strategic positioning has drawn interest from multinational partners, the company added.
Senhwa expects multiple value-driving catalysts over the next one to three years, including clinical data readouts for CX-5461 and CX-4945, expansion of global partnerships, potential licensing collaborations and increased visibility at international medical conferences such as ASCO, AACR and ESMO.
“Senhwa has transitioned beyond early-stage discovery and development into a company building a scalable, AI-validated oncology platform,” the company said, adding that it is focused on advancing differentiated science to create long-term value for patients, partners and shareholders.
Leave a Reply